MedTrace Logo

Validation of 70-gene MammaPrint Profile in Japanese Population

NCT00904566 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 102

Last updated 2015-06-23

No results posted yet for this study

Summary

By using gene-expression profiling, Van't Veer and colleagues developed a 70-gene prognosis profile, MammaPrint, to identify breast cancer patients who are at low risk of developing distant metastases and therefore might safely be spared chemotherapy. The aim of this study is to evaluate the prognostic value of the 70-gene Mammaprint profile in Japanese women with node-negative breast cancer.

Conditions

Sponsors & Collaborators

  • Osaka General Medical Center

    collaborator OTHER

  • Agendia

    lead INDUSTRY

Principal Investigators

  • Kikuya Kato, MD, PhD, Prof · Osaka Medical Center for Cancer and Cardiovascular Diseases

Eligibility

Min Age
29 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-04-30
Primary Completion
2009-01-31
Completion
2009-01-31

Countries

  • Japan

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00904566 on ClinicalTrials.gov